NASDAQ · Biotechnology

IO Biotech, Inc. (IOBT) Stock

$0.01 -27.59% NASDAQ: IOBT Healthcare

IO Biotech, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating immune-modulating cancer treatments.

Valuation

MetricValue
Price$0.01
Market Cap$885690
P/E Ratio-0.01
P/B Ratio0.90
P/S Ratio0.00
EPS (TTM)$-1.45
52-Week High$2.79
52-Week Low$0.01
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-591.35%
ROA-142.70%
ROCE-300.80%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity1.60
Current Ratio2.01

Annual Financials (USD)

Metric20202021202220232024
Revenue$0$0$0$0$0
Operating Profit$-10.0M$-41.0M$-71.0M$-91.0M$-95.0M
Net Profit$-12.0M$-68.0M$-71.0M$-86.0M$-95.0M
EPS$-1.05$-2.36$-2.48$-1.98$-1.45
Op Margin—————

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$6.0M$222.0M$152.0M$151.0M$68.0M
Total Liabilities$3.0M$10.0M$13.0M$18.0M$21.0M
Cash$3.0M$212.0M$143.0M$143.0M$60.0M
Borrowings$0$0$3.0M$2.0M$2.0M

Latest News

Elevara Medicines Appoints Biotech Veteran as CEO GlobeNewswire · Jul 14, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-10.0M$-41.0M$-60.0M$-72.0M$-82.0M
Investing Cash Flow$0$0$-1.0M$-1.0M$0
Financing Cash Flow$0$-12.0M$0$-3.0M$0
Net Cash Flow$-4.0M$208.0M$-69.0M$1.0M$-83.0M
Free Cash Flow$-10.0M$-41.0M$-60.0M$-72.0M$-82.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA0.50
FCF Yield-6935.72%
Quick Ratio2.01
Interest Coverage-57.16
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACET $8.30 +1.22% -0.46 $77.59M 0.00%
CUE $32.57 +1.40% -4.05 $85.59M 0.00%
HOWL $0.40 -3.04% -0.33 $19.54M 0.00%
INKTMiNK Therapeutics, Inc. $10.97 -0.95% -3.91 $54.63M 0.00%
KPTIKaryopharm Therapeutics Inc. $7.60 +2.56% -0.50 $172.24M 0.00%

About IO Biotech, Inc.

IO Biotech, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating immune-modulating cancer treatments. These therapies leverage its proprietary T-win technology platform. The company's primary investigational drug, IO102-IO103, is engineered to counteract immunosuppressive proteins such as Indoleamine 2,3-dehydrogenase (IDO) and programmed death-ligand (PD-L1). This candidate is progressing through Phase 2 clinical trials for melanoma and is also being evaluated in Phase 1 trials across a range of other cancers, including lung, head and neck, bladder, and melanoma. Additionally, IO Biotech is developing IO112, a distinct product candidate. IO112 comprises a single Arginase 1-derived peptide designed to specifically target T cells that identify epitopes originating from Arginase 1, aiming to treat various malignancies. Established in 2014, the company is headquartered in Copenhagen, Denmark.

IO Biotech, Inc. is headquartered in DK.

IO Biotech, Inc. (IOBT) stock trades at $0.01 with a market capitalization of $885690. The stock is valued at a price-to-earnings (P/E) ratio of -0.01, price-to-book of 0.90, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.01 and $2.79, and currently trades 99.6% below its 52-week high.

On profitability, IO Biotech, Inc. generates a return on equity (ROE) of -591.35%, return on capital employed of -300.80%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.iobiotech.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides